Standard therapy of HER2-positive and triple negative metastatic breast cancer - present and future

2013 ◽  
Vol 21 (3-4) ◽  
pp. 163-167
Author(s):  
Jasna Trifunovic ◽  
Jasna Pesic
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Standard Therapy ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Her2 Positive

nema

scholarly journals Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer

2019 ◽  
Vol 79 (10) ◽  
pp. 1079-1089 ◽  
Author(s):  
Florian Schütz ◽  
Peter A. Fasching ◽  
Manfred Welslau ◽  
Andreas D. Hartkopf ◽  
Achim Wöckel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Homologous Recombination ◽  
Early Breast Cancer ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Parp Inhibitors ◽  
Her2 Positive ◽  
Hormone Receptor Positive ◽  
Further Development

AbstractThe further development of therapies for women with early breast cancer is progressing far more slowly than in the case of patients with advanced breast cancer and is additionally delayed compared to developments in metastatic breast cancer. Nonetheless, significant advancements have been able to be recorded recently. This review summarises the latest developments in view of the most recent publications and professional conferences. For hormone-receptor-positive patients, new aspects for the duration of antihormone therapy and with regard to the benefits of multigene tests have been published. In the case of HER2-positive patients, the value of post-neoadjuvant therapy and de-escalation of the therapy is discussed. In patients with triple-negative breast cancer, there is a question of whether the knowledge of the biological background of a homologous recombination deficiency (HRD) helps develop new therapies for this subtype. In particular the “use” of a BRCA1/2 mutation or the biological characteristic HRD as a potential motive for therapy plays a role here in specifying the significance of platinum therapy and therapy with PARP inhibitors.

scholarly journals Clinical Outcomes of Metastatic Breast Cancer in Patients Having Both Pseudocirrhosis and Portal Hypertension with Evident Varices

2021 ◽  
Author(s):  
Wei-Li Ma ◽  
Dwan-Ying Chang ◽  
Ching-Hung Lin ◽  
Kao-Lang Liu ◽  
Po-Chin Liang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Cirrhosis ◽  
Metastatic Breast Cancer ◽  
Portal Hypertension ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
De Novo ◽  
Imaging Finding ◽  
Metastatic Breast ◽  
Her2 Positive

Abstract Background: Pseudocirrhosis is an imaging finding of malignancies with liver metastasis with or without clinical liver cirrhosis–related complications such as portal hypertension (pHTN). This study compared the outcomes of metastatic breast cancer in patients with imaging-diagnosed pseudocirrhosis with or without pHTN. Methods: The medical records from patients with metastatic breast cancer and pseudocirrhosis between 2005 and 2017 were retrospectively analyzed. Clinical pHTN was defined based on endoscopic evidence of esophageal or gastric varices. Results: Among 106 patients with pseudocirrhosis, 33 (31%) had de novo stage IV disease, and 66 (62%) had hormone receptor (HR)–positive and human epidermal growth factor receptor 2 (HER2)–negative breast cancer. In total, 81 (76%) had initial metastases in both hepatic lobes, 91 (86%) had 4 or more liver metastases, and 32 (30%) had pHTN. The median overall survival (OS) was 5 and 13 months in patients with and without pHTN, respectively (p = .002). The median OS in patients with HER2-positive, HR-positive/HER2-negative, and triple-negative breast cancer was 16, 9, and 2 months, respectively (p = .001). Patients with pHTN generally had cirrhotic complications, including gastrointestinal bleeding, hyperbilirubinemia, hyperammonemia, and coagulopathy. Despite their challenging clinical conditions, 7 patients with pHTN had OS exceeding 1 year. In multivariate analysis, pHTN (p = .007) and triple-negative breast cancer (p = .013) were associated with poor OS. Conclusions: For patients with pseudocirrhosis, clinical pHTN was associated with liver cirrhosis–related complications and shorter median OS. A few patients with pHTN had prolonged OS with effective systemic treatment and aggressive supportive care.

scholarly journals Dissemination of Circulating Tumor Cell Clusters Occurs Early in Non‑metastatic Breast Cancer Patients

2021 ◽  
Author(s):  
Carolina Reduzzi ◽  
Serena Di Cosimo ◽  
Lorenzo Gerratana ◽  
Rosita Motta ◽  
Antonia Martinetti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Cell ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Circulating Tumor Cell ◽  
Cluster Detection ◽  
Her2 Positive ◽  
Blood Samples ◽  
Cell Clusters

Abstract Background: Metastatic spreading is promoted by cancer cell seeding from the primary tumor into the bloodstream. In patients with metastatic breast cancer (MBC), the clinical relevance of circulating tumor cell clusters (CTC-clusters) has been extensively reported, while their study in earlier stages is limited. Several methods, besides the FDA-cleared CellSearch®, limited to the detection of epithelial-enriched clusters, can be used for the detection of CTC-clusters. We hypothesize that resorting to marker-independent approaches can improve CTC-cluster detection. Methods: Blood samples collected from healthy donors and spiked-in with tumor mammospheres, or from BC patients, were processed for CTC-cluster detection with 3 technologies: CellSearch®, CellSieve™ filters, ScreenCell® filters. The number of CTC-clusters was compared among the technologies and analyzed in relation to patient characteristics and outcome. Results: In spiked-in samples, the 3 technologies showed similar capability of recover epithelial mammospheres, whereas, in a series of 19 clinical samples processed in parallel with the CellSearch® and CellSieve™ filters (that allow the detection of both epithelial and non-epithelial clusters), CTC-clusters were detected in 53% of samples with the CellSearch®, versus 79% and 84% with the CellSieve™, when considering only epithelial or both epithelial and non-epithelial clusters, respectively. Next, blood samples from 37 non-metastatic breast cancer (NMBC) and 23 MBC patients were processed using ScreenCell® filters for attaining both unbiased enrichment and marker-independent identification of clusters based on cytomorphological criteria. At baseline, CTC-clusters were detected in 70% of NMBC cases and in 20% of MBC patients (median number= 2, range 0–20, versus 0, range 0‑15, P =0.0015). Among NMBC patients, clusters were slightly higher in women with node-positive than node‑negative status (0 versus 3, P =0.1110 ) and were more frequently observed in women with luminal‑like and triple-negative tumors than in patients with HER2-positive disease (median CTC-cluster number =4, 5, and 0 for luminal‑like, triple-negative, and HER2-positive BC, respectively, P =0.0467). Conclusions: We demonstrated that CTC-cluster detection can be improved by a marker-independent enrichment and identification, and we reported that CTC-clusters are more frequently detected in NMBC than in MBC patients, suggesting that dissemination of CTC-clusters is an early event in BC natural history.

Sign in / Sign up

Export Citation Format

Share Document